Sort
48,018 grants matching “immunotherapy”
MOLECULAR MECHANISMS OF TUMOR-INDUCED TOLERANCE
$363,450Lieping Chen · Johns Hopkins University · R01 · FY2009 · CA
TOWARD AN UNDERSTANDING OF CLL PROGRESSION
$363,375Carlo M Croce · Ohio State University · R01 · FY2014 · CA
Targeting the vasculature to enhance anti-tumor immunity
$363,375Andrew Carl Dudley · University Of Virginia · R01 · FY2020 · CA
Targeting Translation Dependence in Colorectal Cancer Progression
$363,375Qing-Bai She · University Of Kentucky · R01 · FY2021 · CA
Targeting the vasculature to enhance anti-tumor immunity
$363,375Andrew Carl Dudley · University Of Virginia · R01 · FY2021 · CA
Targeting Translation Dependence in Colorectal Cancer Progression
$363,375Qing-Bai She · University Of Kentucky · R01 · FY2020 · CA
Epigenomic control of antimicrobial immunity in the intestine
$363,361Theresa Alenghat · Cincinnati Childrens Hosp Med Ctr · R01 · FY2019 · DK
THE HYPEREOSINOPHILIC SYNDROMES AND MEPOLIZUMAB
$363,355University Of Utah · R01 · FY2004 · AI
Correlates of antitumor immunity in colorectal cancers and anti PD1 therapy
$363,340Franck Housseau · Johns Hopkins University · R01 · FY2019 · CA
Cell Therapy Core
$363,333Victor M Lemas · Johns Hopkins University · P01 · FY2022 · CA
Cell Therapy Core
$363,333Victor M Lemas · Johns Hopkins University · P01 · FY2020 · CA
Cell Therapy Core
$363,333Victor M Lemas · Johns Hopkins University · P01 · FY2021 · CA
Laboratory and Clinical studies on T-cells recognizing NSCLC
$363,308James C Yang · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Project 1
$363,288Mark M. Awad · Dana-Farber Cancer Inst · P50 · FY2022 · CA
Project 2: The Impact of Immunotherapy on Human Vaccination
$363,288E. John Wherry · Massachusetts General Hospital · U19 · FY2022 · AI
EASTERN COOPERATIVE ONCOLOGY GROUP
$363,280Tufts Medical Center · U10 · FY2001 · CA
Programmable Off-the-Shelf Dendritic Cells as an Immunotherapy Discovery Platform
$363,248David Minh Truong · New York University · DP2 · FY2023 · AI
Defining the Role of the Cancer Circadian Clock in Tumor Immunity and Tumorigenesis
$363,222Chi V. Dang · Wistar Institute · R01 · FY2022 · CA
Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy
$363,204Drew M. Pardoll · Johns Hopkins University · R01 · FY2019 · CA
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer
$363,165Don Lynn Gibbons · University Of Tx Md Anderson Can Ctr · R37 · FY2023 · CA
Bayesian Methods for Complex Precision Biotherapy Trials in Oncology
$363,164Peter F Thall · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
$363,164Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy
$363,164Wei Gu · Columbia University Health Sciences · R01 · FY2022 · CA
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
$363,164Juan Fueyo · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
$363,164Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA